Immuron (STU:ANWA) Institutional Ownership : 0.30% (As of Jun. 07, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Immuron Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immuron's institutional ownership is 0.30%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immuron's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immuron's Float Percentage Of Total Shares Outstanding is 0.00%.

Immuron Institutional Ownership Historical Data

The historical data trend for Immuron's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Institutional Ownership Chart

Immuron Historical Data

The historical data trend for Immuron can be seen below:

	2021-02-28	2021-03-31	2021-04-30	2021-05-31	2021-06-30	2021-07-31	2021-08-31	2021-09-30	2021-10-31	2021-11-30
Institutional Ownership	0.44	0.58	0.58	0.58	0.54	0.54	0.54	0.54	0.37	0.30

Immuron Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Immuron (STU:ANWA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines